Skip to main content
Esc

Type to search

Articles / venture-startup-funding / Glass House Brands Reports First Quarter 2026 Financial Results

Glass House Brands Reports First Quarter 2026 Financial Results

Q1 2026 Revenue
$40.5 million
Total revenue reported for the first quarter of 2026.
Average Selling Price
$171 per pound
Average price per pound of cannabis sold in Q1 2026.
Projected Cannabis Biomass Production
1,000,000 pounds
Estimated total cannabis biomass production for the year 2026.

⦿ Executive Snapshot

  • What: Glass House Brands reports Q1 2026 financial results with a revenue of $40.5 million.
  • Who: Glass House Brands Inc., Kyle Kazan (Co-Founder, Chairman and CEO).
  • Why it matters: The report highlights significant challenges in production costs and pricing, alongside potential regulatory shifts that could impact future operations and profitability.

⦿ Key Developments

  • Revenue for Q1 2026 was $40.5 million, a decrease from $44.8 million in Q1 2025 and $38.9 million in Q4 2025.
  • The average selling price was $171 per pound, down from $193 in Q1 2025.
  • The company anticipates producing approximately 1,000,000 pounds of cannabis biomass in 2026, maintaining its full-year guidance.

⦿ Strategic Context

  • Glass House Brands operates in a challenging California cannabis market, facing reduced wholesale prices and increased production costs.
  • The recent rescheduling of medical cannabis under Schedule III may provide opportunities for tax relief and market expansion, significantly impacting growth potential.

⦿ Strategic Implications

  • Immediate implications include a need to adjust operations to manage rising production costs and competitive pricing pressures.
  • Long-term, the potential deregulation and market expansion could lead to increased revenue and profitability if executed effectively.

⦿ Risks & Constraints

  • Potential risks include regulatory uncertainties and dependence on the successful implementation of new operational strategies amid a fluctuating market.
  • Competition from other cannabis producers and the necessity to innovate in product offerings may constrain growth.

⦿ Watchlist / Forward Signals

  • Key upcoming milestones include the completion of the Greenhouse 2 build-out and the anticipated regulatory changes regarding medical cannabis.
  • The effectiveness of the newly launched ATM program for capital raising will be crucial for funding future expansions and operations.
§ 08

Related Articles